DOWNLOAD THIS SLIDE KIT

• Pilot, open-label study
• 35 adults on salvage therapy with enfuvirtide-based regimen and HIV-1 RNA < 50 c/mL
• Switch of enfuvirtide to RAL 400 mg bid, the remainder of the salvage regimen being unchanged. At the time of the switch:
  • ENF had been administered for a median of 25 months
  • HIV-1 RNA was < 50 c/mL for a median of 24 months
  • Salvage regimen: 1 to 4 NRTIs, 1 NNRTI in 6 patients, 1 to 2 PIs
• Median follow-up of 7 months (range 1-13 months)
  • 34/35 patients maintained HIV-1 RNA < 50 c/mL
  • 1 single blip at 60 c/mL
  • ENF-related injection site reactions resolved in all patients
  • RAL was well tolerated